Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

New Study to Test Dendritic Cell Immunotherapy Treatment on Mesothelioma

A Netherlands-based biotechnology company has announced progress on its phase II/III mesothelioma study, looking at the impact of its dendritic cell therapy on patients diagnosed with the rare and deadly asbestos-caused cancer. Amphera B.V.’s entire focus is on dendritic cell therapy, and is currently planning three different clinical trials: this is its first, which will focus on pleural mesothelioma patients, while its second will look to the effectiveness of the treatment on peritoneal mesothelioma and third has not yet been announced.

Dendritic Cell Therapy Is Based on Vaccine Science

The basic theory behind dendritic cell therapy, whether it is used on mesothelioma or any other cancer, is to create a tailored cancer vaccine that uses a patient’s own cancer to enhance their immunity against its return. By isolating a fragment of mesothelioma and then combining it with blood from the patient which has gone through a special filtering process, the company isolates a part of the immune system that fights cancer. These cells are then exposed to the fragment of the cancer in the lab and then returned to the patient’s body to protect against the cancer’s spread.

Study Recruits 230 Pleural Mesothelioma Patients

Amphera’s phase II/III study is called DENIM, which stands for DENdritic cell Immunotherapy for Mesothelioma. The company has already recruited 230 pleural mesothelioma patients, half of whom will receive 3 bi-weekly injections of the company’s drug MesoPher following chemotherapy, followed by supportive care and then more injections at weeks 18 and 30. The control group will simply receive supportive care. The two groups will be compared for the duration of their overall survival as well as progression free survival. The patients were recruited from several different mesothelioma centers across Europe.

Speaking of the importance of the study, Amphera’s CEO Rob Meijer said, “The number of pleural mesothelioma patients is on the rise and to date there is only one therapy registered with limited clinical benefit. As such, new approaches to treating mesothelioma are much needed to improve the prognosis for these patients.” 

Every day scientists are creating new ways to fight malignant mesothelioma. Though this therapy is still in the testing phases, there are others that are available to provide victims of asbestos-related diseases with improved quality of life and survival times. For more information, contact the Patient Advocates at Mesothelioma.net at  1-800-692-8608.

Terri Oppenheimer

Terri Oppenheimer is an experienced blog writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of expertise include health, medical research, and law.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –
1-800-692-8608


Site Navigation

Where can I

Get Additional Help?

For over 20 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –
1-800-692-8608

We are here to help you

support_staff

If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

$30 Billion Asbestos Trusts
Get Started